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Table: 828P
SSE, n (%)a All patients
N¼ 333
Prior Abi
n¼ 67
EOD 0–2
(20 meta-
static lesions)
n¼ 149
EOD 3–4
(>20 meta-
static
lesions)
n¼ 165
During Ra-223
treatment
8/312 (2.6) 3/57 (5.3) 0/144 (0) 8/151 (5.3)
Follow-up after
end of Ra-223
treatment
6/162 (3.7) 2/28 (7.1) 1/84 (1.2) 5/74 (6.8)
During long-term
follow-upb
21/144 (14.6) 7/30 (23.3) 9/71 (12.7) 12/70 (17.1)
Over the course of
the study EBRT
Pathological
fractures Spinal
cord compres-
sion Surgical
intervention
33/315 (10.5)
24/315
(7.6) 10/
315 (3.2) 8/
315 (2.5) 6/
315 (1.9)
12/59 (20.3)
9/59 (15.3)
2/59 (3.4)
2/59 (3.4)
1/59 (1.7)
10/145 (6.9)
5/145 (3.4)
5/145 (3.4)
3/145 (2.1)
4/145 (2.8)
23/153
(15.0) 19/
153 (12.4)
5/153
(3.3) 5/
153 (3.3)
2/153
(1.3)
aPercentages calculated based on number of pts for whom documenta-
tion was available within the specified time period.
b>30 days after treatment completion.
Conclusions: Pts previously treated with Abi received Ra-223 18.9mo after CRPC diag-
nosis, had generally received prior chemotherapy and had higher tumour burden, result-
ing in 11.2momedianOS. Pts with higher tumour burden or prior Abi hadmore SSEs,
mainly related to EBRT use; frequency of fractures was low and similar across groups.
Clinical trial identification:NCT02398526.
Editorial acknowledgement:Medical writing support was provided by Risha Bulusu,
MSc, of Scion, London UK.
Legal entity responsible for the study: Bayer.
Funding: Bayer.
Disclosure: T. Neußer: Employee: Bayer Healthcare; Holds stocks: Bayer. J. Kalinovsky:
Employee: BayerHealthcare. All other authors have declared no conflicts of interest.
829P Pain and quality of life in metastasized Castration Resistant Prostate
Cancer patients treated with Radium-223 (ROTOR registry): A
prospective observational registry in a non-study population
R. Louhanepessy1, S. Badrising2, V. Vd Noort3, J.L. Coenen4, A. Oostdijk5, P. Hamberg6,
J.M. Zuetenhorst6, A. Beeker7, N. Wagenaar8, M. Lam9, F. Celik10, E. Vegt11, W. Zwart12,
A. Bergman12
1Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-
AVL), Amsterdam, Netherlands, 2Pulmonary Diseases, Radboud University Medical
Center, Nijmegen, Netherlands, 3Biometrics, Netherlands Cancer Institute-Antoni van
Leeuwenhoek, Amsterdam, Netherlands, 4Medical Oncology, Isala Klinieken, Zwolle,
Netherlands, 5Nuclear Medicine, Isala Klinieken, Zwolle, Netherlands, 6Medical
Oncology, St Franciscus Gasthuis, Rotterdam, Netherlands, 7Internal Medicine, Spaarne
Ziekenhuis, Hoofddorp, Netherlands, 8Nuclear Medicine, Ziekenhuisgroep Twente,
Hengelo, Netherlands, 9Nuclear Medicine, University Medical Center Utrecht, Utrecht,
Netherlands, 10Nuclear Medicine, Deventer Ziekenhuis, Deventer, Netherlands, 11Nuclear
Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam,
Netherlands, 12Division of Internal Medicine (MOD) and Oncogenomics, Division of
Internal Medicine (MOD) and Oncogenomics, Amsterdam, Netherlands
Background: In the ALSYMPCA study a survival benefit of Radium-223 (Ra-223)
treated metastasized Castration Resistant Prostate Cancer (mCRPC) patients with
bone disease was established. However, the effect of Ra-223 treatment on pain and
Quality of Life (QoL) was not explored. 200 mCRPC patients treated with Ra-223 in 20
Dutch hospitals were included in the prospective ROTOR registry.
Methods:QoL (FACT-P) and pain (BPI-S) were recorded at Base-Line (BL) and at
every Ra-223 cycle. Patients with complete questionnaires at BL and at least one on
treatment were included in the analysis. Patients with a BPI-S Pain At ItsWorst
(PAIW) of 4 were considered symptomatic. A decrease of FACT-P and BPI-S PAIW
of 6 points and2 points, respectively, were considered clinically meaningfull.
Results:Currently, data is collected from244 patients. In 101 (41%) patientsQoL and pain
could be evaluated.Mean agewas 72.9 (range 47.8-89.8) years, 85 (83%) had6 bonemeta-
stases, an average of 4.8 (CI 4.6-5.1) cycles were administered and 51 (50%)were treated
with 6 cycles. Themean total FACT-P inwas 70.6 (CI 68.4-72.8). The lowest FACT-P score
was at cycle 3 (67.6; CI65.0-70.1) andwas 67.0 (CI 66.3-73.6) at cycle 6, whichwere 3.0 and
3.6 points lower than BL, respectively. Themean total BPI-S scorewas 43.5 (CI 38.9-48.0) at
baseline. Asymptomatic patients (57; 56%) had a PAIW score of 2.1 (CI 1.8-2.5) and amean
total score of 31.0 (CI 25.9-36.0) at base line. The lowest PAIW score was at cycle 5 (1.7; CI
1.1-2.2) andmean total score of 23.4 (CI 16.2-30.6). Symptomatic patients (54; 53%) had a
PAIWof 6.9 (CI 6.5-7.2) and amean total score of 56.0 (CI 51.0-60.9). The lowest PAIW
score was at cycle 2 (6.1; CI 5.6-6.6) andmean total score of 53.2 (CI 44.9-59.4)whichwere
0.8 and 2.8 points lower than base line, respectively. Patients treatedwith 6 cycles of Ra-223
had a PAIWof 7.1 (CI 6.1-8.2) and amean score of 56.1 (CI 35.5-67.7).
Conclusions:QoL and pain remained stable during Ra-223 treatment. The lack of pain
response might be related to opiate use, which will be analyzed.
Clinical trial identification:NCT03223727.
Legal entity responsible for the study:Netherlands Cancer Institute-Antoni van
Leeunwenhoek hospital.
Funding: Bayer.
Disclosure: A. Bergman: Grants: Bayer BV. All other authors have declared no conflicts
of interest.
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Background: INO-5150 (PSA and PSMA)þ/- INO-9012 (IL-12), a synthetic DNA
immunotherapy, was assessed for safety, immunogenicity and efficacy in biochemically
recurrent prostate cancer patients (pts).
Methods: Phase I, open-label, multi-center study in the US included pts with rising
PSA after surgery and/or RT, PSA doubling time (PSADT)>3months (mos), testoster-
one>150 ng/dL and no concurrent ADT. Safety, immunogenicity and efficacy (PSA
kinetics, PFS) were evaluated in 4 treatment arms of 15 pts each. Arms A: 2mg INO-
5150, B: 8.5mg INO-5150, C: 2mg INO-5150þ 1mg INO-9012 and D: 8.5mg INO-
5150þ 1mg INO-9012. Pts received 4 IM doses of vaccine followed by electroporation
on day 0, wks 3, 12 and 24 and were followed for 72 wks.
Results: 50/61 (82%) pts completed all visits and treatments were well tolerated with
no safety concerns. Median PFS for overall population [N¼ 61, baseline (D0) PSADT
range (mos) 1.5-217.1, median 9.8] and for a subset of pts with D0 PSADT12mos
(N¼ 36) has not yet been reached (FU 3-19mos). 86% of pts with D0 PSADT12mos
were progression free through 19mos FU. 27 out of 36 (75%) pts with D0 PSADT 12
mos had disease stabilization at wks 27 evidenced by significant improvement in
log2PSA change over time (slope) and PSADT fromD0 (Slope¼0.19 declined to 0.1,
PSADT¼5.3 improved to 10.1 mos, p¼<0.0001). This effect was maintained at wk 72
(Slope¼0.09, PSADT¼10.6, p¼<0.0001). Immunogenicity was observed in 77% (47/
61) of pts by multiple immunologic assessments. Patient immunogenicity to INO-5150
as determined by CD38 and PerforinþCD8 T cell immune reactivity correlated with
attenuated % PSA rise compared to pts without reactivity (p¼ 0.05, n¼ 50).
Conclusions: INO-5150þ/- INO-9012 was safe, well tolerated and immunogenic.
Clinical efficacy was observed in the patients with D0 PSADT 12mos as evidenced by
a significant dampening of log2PSA change over time and increased PSADT up to 72
weeks FU. Additional genomic analyses are ongoing to further elucidate the correlation
of immunologic efficacy and clinical benefit. (NCT02514213).
Clinical trial identification: FDA IND number 15870.
Legal entity responsible for the study: Inovio Pharmaceuticals, Inc.
Funding: Inovio Pharmaceuticals, Inc.
Disclosure:N. Shore: Consulting or advisory role for multiple pharmaceutical compa-
nies. E.I. Heath: Consulting or advisory role and honoraria or funding received for
multiple pharmaceutical companies. H. Cheng, Y.Whang: Funding received frommul-
tiple pharmaceutical companies. K. Bhatt, M.Morrow, T. McMullan, K. Kraynyak, J.
Lee, B. Sacchetta, L. Liu, S. Rosencranz, I. Csiki, M.L. Bagarazzi: Employee of the phar-
maceutical company sponsoring this research trial. S.T. Tagawa, R. Tutrone, J. Garcia,
W. Kelly: Consulting or advisory role and funding received frommultiple pharmaceut-
ical companies. All other authors have declared no conflicts of interest.
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